ario pharma

Ario Pharma Ltd is developing new therapeutics for the treatment of pain.

A TRPA1 lead optimisation project is underway, focusing on chronic pain: The company is actively working to identify potent, safe, orally bioavailable small molecule TRPA1 antagonists to treat neuropathic and inflammatory pain.

The Company developed a best-in-class oral TRPV1 inhibitor that was acquired by PILA Pharma in 2016 and will be evaluated in patients with Type-2 diabetes.

Find out more

Please contact us to arrange a meeting at one of the events we are attending.

latest news

Ario Pharma Acquires PharmEste’s TRPA1 Research Assets

more news from ario pharma